Ex ni­hi­lo: Take­da leads $100M+ round to fund biotech's sneak at­tack on tu­mors, pro­pelling new IL-2, CT­LA-4 drugs to clin­ic

Since emerg­ing out of stealth in 2018 with $30 mil­lion in launch mon­ey from At­las and F-Prime, Akre­via has kept a rel­a­tive­ly low pro­file, ham­mer­ing away at its plat­form tech­nol­o­gy to de­sign im­munother­a­pies with all their po­ten­cy but lit­tle of their side ef­fects. With an of­fi­cial CEO in place for al­most a year — and now a new name — the biotech is ready to step up with an­oth­er $100.5 mil­lion to bring its two lead com­pounds in­to the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER